Abstract
Cardiac hypertrophy is promoted by adrenergic over-activation and represents an independent risk factor for cardiovascular morbidity and mortality. The basic knowledge about mechanisms by which sustained adrenergic activation promotes myocardial growth, as well as understanding how structural changes in hypertrophied myocardium could affect myocardial function has been acquired from studies using an animal model of chronic systemic β-adrenoreceptor agonist administration. Sustained β-adrenoreceptor activation was shown to enhance the synthesis of myocardial proteins, an effect mediated via stimulation of myocardial growth factors, up-regulation of nuclear proto-oncogenes, induction of cardiac oxidative stress, as well as activation of mitogen-activated protein kinases and phosphatidylinositol 3-kinase. Sustained β-adrenoreceptor activation contributes to impaired cardiac autonomic regulation as evidenced by blunted parasympathetically-mediated cardiovascular reflexes as well as abnormal storage of myocardial catecholamines. Catecholamine-induced cardiac hypertrophy is associated with reduced contractile responses to adrenergic agonists, an effect attributed to downregulation of myocardial β-adrenoreceptors, uncoupling of β-adrenoreceptors and adenylate cyclase, as well as modifications of downstream cAMP-mediated signaling. In compensated cardiac hypertrophy, these changes are associated with preserved or even enhanced basal ventricular systolic function due to increased sarcoplasmic reticulum Ca2+ content and Ca2+-induced sarcoplasmic reticulum Ca2+ release. The increased availability of Ca2+ to maintain cardiomyocyte contraction is attributed to prolongation of the action potential due to inhibition of the transient outward potassium current as well as stimulation of the reverse mode of the Na+–Ca2+ exchange. Further progression of cardiac hypertrophy towards heart failure is due to abnormalities in Ca2+ handling, necrotic myocardial injury, and increased myocardial stiffness due to interstitial fibrosis.
Similar content being viewed by others
References
Levy D, Garrison RJ, Savage DD et al (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566
Haider AW, Larson MG, Benjamin EJ et al (1998) Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32:1454–1459
Sundstrom J, Lind L, Arnlov J et al (2001) Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 103:2346–2351
Okin PM, Devereux RB, Nieminen MS et al (2006) Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 113:67–73
Drazner MH, Rame JE, Marino EK et al (2004) Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years. J Am Coll Cardiol 43:2207–2215
Martini G, Rabbia F, Gastaldi L et al (2001) Heart rate variability and left ventricular diastolic function in patients with borderline hypertension with and without left ventricular hypertrophy. Clin Exp Hypertens 23:77–87
Schafer S, Kelm M, Mingers S et al (2002) Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. J Hypertens 20:1431–1437
Passino C, Magagna A, Conforti F et al (2003) Ventricular repolarization is prolonged in nondipper hypertensive patients: role of left ventricular hypertrophy and autonomic dysfunction. J Hypertens 21:445–451
Verdecchia P, Schillaci G, Borgioni C et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48–54
Mathew J, Sleight P, Lonn E et al (2001) Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615–1621
Strand AH, Gudmundsdottir H, Os I et al (2006) Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens 24:905–913
Greenwood JP, Scott EM, Stoker JB et al (2001) Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 38:1711–1717
Schlaich MP, Kaye DM, Lambert E et al (2003) Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108:560–565
Kelm M, Schafer S, Mingers S et al (1996) Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 14:1365–1367
Schlaich MP, Kaye DM, Lambert E et al (2005) Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens 23:1077–1082
Chappel CI, Rona G, Balazs T et al (1951) Severe myocardial necrosis produced by isoproterenol in the rat. Arch Int Pharmacodyn 72:123–128
Handforth CP (1962) Isoproterenol-induced myocardial infarction in animals. Arch Pathol 73:83–87
Maruffo CA (1967) Fine structural study of myocardial changes induced by isoproterenol in rhesus monkeys (Macaca mulatta). Am J Pathol 50:27–34
Ostadal B, Rychterova V, Poupa O (1968) Isoproterenol-induced acute experimental cardiac necrosis in the turtle (Testudo horsfieldi). Am Heart J 76:645–649
Rona G, Chappel CI, Balazs T et al (1959) The effect of breed, age, and sex on myocardial necrosis produced by isoproterenol in the rat. J Gerontol 14:169–173
Rona G, Chappel CI, Balazs T et al (1959) An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Arch Pathol 67:443–455
Rona G, Chappel C, Kahn DS (1963) The significance of factors modifying the development of isoproterenol-induced myocardial necrosis. Am Heart J 66:389–395
Rona G (1985) Catecholamine cardiotoxicity. J Mol Cell Cardiol 17:291–306
Bloom S, Cancilla PA (1969) Myocytolysis and mitochondrial calcification in rat myocardium after low doses of isoproterenol. Am J Pathol 54:373–381
Stanton HC, Brenner G, Mayfield ED (1969) Studies on isoproterenol-induced cardiomegaly in rats. Am Heart J 77:72–80
Collins P, Billings CG, Barer GR et al (1975) Quantitation of isoprenaline-induced changes in the ventricular myocardium. Cardiovasc Res 9:797–806
Benjamin IJ, Jalil JE, Tan LB et al (1989) Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65:657–670
Alderman EL, Harrison DC (1971) Myocardial hypertrophy resulting from low dosage isoproterenol administration in rats. Proc Soc Exp Biol Med 136:268–270
Gordon AL, Inchiosa MA, Lehr D (1972) Isoproterenol-induced cardiomegaly: assessment of myocardial protein content, actomyosin ATPase and heart rate. J Mol Cell Cardiol 4:543–557
Pagano VT, Inchiosa MA (1977) Cardiomegaly produced by chronic beta-adrenergic stimulation in the rat: comparison with alpha-adrenergic effects. Life Sci 21:619–624
Tse J, Powell JR, Baste CA et al (1979) Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of β-adrenergic receptor, adenylate cyclase, and ventricular contraction. Endocrinology 105:246–255
Baldwin KM, Ernst SB, Mullin WJ et al (1982) Exercise capacity and cardiac function of rats with drug-induced cardiac enlargement. J Appl Physiol 52:591–595
Chang HY, Klein RM, Kunos G (1982) Selective desensitization of cardiac beta-adrenoceptors by prolonged in vivo infusion of catecholamines in rats. J Pharmacol Exp Ther 221:784–789
Chatelain P, Robberecht P, De Neef P et al (1982) Early decrease in secretin-, glucagon-, and isoproterenol-stimulated cardiac adenylate cyclase activity in rats treated with isoproterenol. Biochem Pharmacol 31:347–352
Nomura Y, Kajiyama H, Segawa T (1982) Alteration in sensitivity to isoproterenol and acetylcholine in the rat heart after repeated administration of isoproterenol. J Pharmacol Exp Ther 220:411–416
Clarke K, Ward LC (1983) Protein synthesis in the early stages of cardiac hypertrophy. Int J Biochem 15:1267–1271
Taylor PB, Tang Q (1984) Development of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol 62:384–389
Gengo P, Skattebol A, Moran JF et al (1988) Regulation by chronic drug administration of neuronal and cardiac calcium channel, beta-adrenoceptor and muscarinic receptor levels. Biochem Pharmacol 37:627–633
Nanoff C, Freissmuth M, Tuisl E et al (1989) A different desensitization pattern of cardiac β-adrenoceptor subtypes by prolonged in vivo infusion of isoprenaline. J Cardiovasc Pharmacol 13:198–203
Bowling N, Wyss VL, Gengo PJ et al (1990) Cardiac inotropic responses to calcium and forskolin are not altered by prolonged isoproterenol infusion. Eur J Pharmacol 187:155–164
Brand T, Sharma HS, Schaper W (1993) Expression of nuclear proto-oncogenes in isoproterenol-induced cardiac hypertrophy. J Mol Cell Cardiol 25:1325–1337
Golomb E, Abassi ZA, Cuda G et al (1994) Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am J Physiol 267:H1496–1506
Boluyt MO, Long X, Eschenhagen T et al (1995) Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am J Physiol 269:H638–647
Muller FU, Boknik P, Horst A et al (1995) In vivo isoproterenol treatment leads to downregulation of the mRNA encoding the cAMP response element binding protein in the rat heart. Biochem Biophys Res Commun 215:1043–1049
Sarsero D, Molenaar P (1995) Effects of chronic infusion of (-)-isoprenaline on rat cardiac muscarinic M2-cholinoceptors and β1-and β2-adrenoceptors. J Auton Pharmacol 15:239–255
Hakamata N, Hamada H, Ohsuzu F et al (1997) Cardiac β-adrenergic signaling pathway alteration in isoproterenol-induced cardiac hypertrophy in male Sprague-Dawley rats. Jpn Heart J 38:849–857
Masson S, Arosio B, Luvara G et al (1998) Remodelling of cardiac extracellular matrix during β-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J Mol Cell Cardiol 30:1505–1514
Suzuki J, Ohno I, Nawata J et al (1999) Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol 34:635–644
Takemoto Y, Yoshiyama M, Takeuchi K et al (1999) Increased JNK, AP-1 and NF-kB DNA binding activities in isoproterenol-induced cardiac remodelling. J Mol Cell Cardiol 31:2017–2030
Morisco C, Zebrowski DC, Vatner DE et al (2001) β-adrenergic cardiac hypertrophy is mediated primarily by the β1-subtype in the rat heart. J Mol Cell Cardiol 33:561–573
Brouri F, Findji L, Mediani O et al (2002) Toxic cardiac effects of catecholamines: role of β-adrenoceptor downregulation. Eur J Pharmacol 456:69–75
Brouri F, Hanoun N, Mediani O et al (2004) Blockade of β1- and desensitization of β2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol 485:227–234
Miura S, Ohno I, Suzuki J et al (2003) Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by β-adrenergic stimulation in rats. J Cardiovasc Pharmacol 42:174–181
Tomita H, Nazmy M, Kajimoto K et al (2003) Inducible cAMP early repressor is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to β-adrenergic receptor stimulation. Circ Res 93:12–22
Zhang GX, Kimura S, Nishiyama A et al (2005) Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 65:230–238
Robbins RJ, Swain JL (1992) C-myc protooncogene modulates cardiac hypertrophic growth in transgenic mice. Am J Physiol 262:H590–597
Soonpaa MH, Field LJ (1994) Assessment of cardiomyocyte DNA synthesis during hypertrophy in adult mice. Am J Physiol 266:H1439–1445
Kudej RK, Iwase M, Uechi M et al (1997) Effects of chronic β-adrenergic receptor stimulation in mice. J Mol Cell Cardiol 29:2735–2746
Iaccarino G, Tomhave ED, Lefkowitz RJ et al (1998) Reciprocal in vivo regulation of myocardial G-protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 98:1783–1789
Iaccarino G, Dolber PC, Lefkowitz RJ et al (1999) β-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy. Hypertension 33:396–401
Saadane N, Alpert L, Chalifour LE (1999) Expression of immediate early genes, GATA-4, and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice. Br J Pharmacol 127:1165–1176
Saadane N, Alpert L, Chalifour LE (2000) Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in EGR-1 deficient mice. Am J Physiol 278:H796–805
Zou Y, Yao A, Zhu W et al (2001) Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin. Circulation 104:102–108
Ozaki M, Kawashima S, Yamashita T et al (2002) Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 66:851–856
Chattopadhyay A, Biswas S, Bandyopadhyay D et al (2003) Effect of isoproterenol on lipid peroxidation and antioxidant enzymes of myocardial tissue of mice and protection by quinidine. Mol Cell Biochem 245:43–49
Oudit GY, Crackower MA, Eriksson U et al (2003) Phosphoinositide 3-kinase γ-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108:2147–2152
Yin F, Li P, Zheng M et al (2003) Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart. J Biol Chem 278:21070–21075
Zahabi A, Picard S, Fortin N et al (2003) Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 278:47694–47699
Dostanic S, Servant N, Wang C et al (2004) Chronic β-adrenoreceptor stimulation in vivo decreased Bcl-2 and increased Bax expression but did not activate apoptotic pathways in mouse heart. Can J Physiol Pharmacol 82:167–174
Gava AL, Peotta VA, Cabral AM et al (2004) Decreased baroreflex sensitivity in isoproterenol-treated mice with cardiac hypertrophy. Auton Neurosci 114:47–54
Jaffre F, Callebert J, Sarre A et al (2004) Involvement of the serotonin 5-HT2b receptor in cardiac hypertrophy linked to sympathetic stimulation. Circulation 110:969–974
Faulx MD, Ernsberger P, Vatner D et al (2005) Strain dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice. Am J Physiol 289:H30–36
Hohimer AR, Davis LE, Hatton DC (2005) Repeated daily injections and osmotic pump infusion of isoproterenol cause similar increases in cardiac mass but have different effects on blood pressure. Can J Physiol Pharmacol 83:191–197
Maisel AS, Phillips C, Michel MC et al (1989) Regulation of cardiac β-adrenergic receptors by captopril. Implications for congestive heart failure. Circulation 80:669–675
Gillis AM, Mathison HJ, Patel C et al (1996) Quinidine pharmacodynamics in normal and isoproterenol-induced hypertrophied blood-perfused working rabbit hearts. J Cardiovasc Pharmacol 27:916–926
Kim N, Kim H, Youm JB et al (2006) Site specific differential activation of ras/raf/ERK signaling in rabbit isoproterenol-induced left ventricular hypertrophy. Biochim Biophys Acta 1763:1067–1075
Gans JH, Cater MR (1970) Norepinephrine-induced cardiac hypertrophy in dogs. Life Sci 9:731–740
Laks MM, Morady F, Swan HJC (1973) Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64:75–78
King BD, Sack D, Kichuk MR et al (1987) Absence of hypertension despite chronic marked elevations in plasma norepinephrine in conscious dogs. Hypertension 9:582–590
Patel MB, Stewart JM, Loud AV et al (1991) Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 84:2091–2100
Stewart JM, Patel MB, Wang J et al (1992) Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of LV reserve. Am J Physiol 262:H331–339
Bishopric NH, Kedes L (1991) Adrenergic regulation of the skeletal α-actin gene promoter during myocardial cell hypertrophy. Proc Natl Acad Sci USA 88:2132–2136
Bogoyevitch MA, Andersson MB, Gillespie-Brown J et al (1996) Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J 314:115–121
Jeppsson AB, Waldeck B, Widmark E (1986) Further studies on the cardiomegaly induced by β-adrenoceptor agonists. Acta Pharmacol Toxicol 58:121–125
Schafer M, Frischkopf K, Taimor G et al (2000) Hypertrophic effect of selective β1-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol 279:C495–503
Decker RS, Cook MG, Behnke-Barclay MM et al (1993) Catecholamines modulate protein turnover in cultured, quiescent rabbit cardiac myocytes. Am J Physiol 265:H329–339
Pinson A, Schluter KD, Zhou XJ et al (1993) Alpha- and beta-adrenergic stimulation of protein synthesis in cultured adult cardiomyocytes. J Mol Cell Cardiol 25:477–490
Schluter KD, Zhou XJ, Piper HM (1995) Induction of hypertrophic responsiveness to isoproterenol by TGF-β1 in adult rat cardiomyocytes. Am J Physiol 269:C1311–1316
Yamazaki T, Komuro I, Zou Y et al (1997) Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both α1-and β-adrenoceptors. Circulation 95:1260–1268
Schluter KD, Goldberg Y, Taimor G et al (1998) Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Cardiovasc Res 40:174–181
Ueyama T, Kawashima S, Sakoda T et al (2000) Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol 32:947–960
Luo JD, **e F, Zhang WW et al (2001) Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyoytes. Br J Pharmacol 132:159–164
Singal PK, Kapur N, Dhillon KS et al (1982) Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 60:1390–1397
Teerlink JR, Pfeffer JM, Pfeffer MA (1994) Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 75:105–113
Ng Y, Goldspink DF, Burniston JG et al (2002) Characterisation of isoprenaline myotoxicity on slow-twitch skeletal versus cardiac muscle. Int J Cardiol 86:299–309
Goldspink DF, Burniston JG, Ellison GM et al (2004) Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp Physiol 89:407–416
Li Z, Tran TT, Ma JY et al (2004) p38α mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats. J Cardiovasc Pharmacol 44:486–492
Meng D, Feng L, Chen XJ et al (2006) Trimetazidine improved Ca2+ handling in isoprenaline-mediated myocardial injury of rats. Exp Physiol 91:591–601
Jalil JE, Doering CW, Janicki JS et al (1989) Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 64:1041–1050
Jalil JE, Janicki JS, Pick R et al (1989) Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. Circ Res 65:258–264
Allard MF, De Venny MF, Doss LK et al (1990) Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy. J Mol Cell Cardiol 22:1135–1145
Bhambi B, Eghbali M (1991) Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 139:1131–1142
Omura T, Kim S, Takeuchi K et al (1994) Transforming growth factor β1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. Cardiovasc Res 28:1835–1842
Grimm D, Elsner D, Schunkert H et al (1998) Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res 37:91–100
Grimm D, Holmer SR, Riegger GAJ et al (1999) Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol-induced heart failure in the rat. Cardiovasc Pathol 8:315–323
Yoshiyama M, Takeuchi K, Kim S et al (1998) Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy. Jpn Circ J 62:47–52
Barth W, Deten A, Bauer M et al (2000) Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Mol Cell Cardiol 32:273–284
Gallego M, Espina L, Vegas L et al (2001) Spironolactone and captopril attenuates isoproterenol-induced cardiac remodeling in rats. Pharmacol Res 44:311–315
Leenen FHH, White R, Yuan B (2001) Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol 281:H2410–2416
Ocaranza MP, Diaz-Araya G, Chiong M et al (2002) Isoproterenol and angiotensin I-converting enzyme in lung, left ventricle, and plasma during myocardial hypertrophy and fibrosis. J Cardiovasc Pharmacol 40:246–254
Shizukuda Y, Buttrick PM, Geenen DL et al (1998) β-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol 275:H961–968
Upsher ME, Weiss HR (1986) Heterogeneous distribution of beta-adrenoceptors in the dog left ventricle. J Mol Cell Cardiol 18:657–660
Mori H, Ishikawa S, Kojima S et al (1993) Increased responsiveness of left ventricular apical myocardium to adrenergic stimuli. Cardiovasc Res 27:192–198
Ennis IL, Escudero EM, Console GM et al (2003) Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition. Hypertension 41:1324–1329
Gianuzzi CE, Seidler FJ, Slotkin TA (1995) β-adrenoceptor control of cardiac adenylyl cyclase during development: agonist pre-treatment in the neonate uniquely causes heterologous sensitization, not desensitization. Brain Res 694:271–278
Zeiders JL, Seidler FJ, Slotkin TA (1997) Ontogeny of regulatory mechanisms for β-adrenoceptor control of rat cardiac adenylyl cyclase: targeting of G-proteins and the cyclase catalytic subunit. J Mol Cell Cardiol 29:603–615
Zeiders JL, Seidler FJ, Iaccarino G et al (1999) Ontogeny of cardiac β-adrenoceptor desensitization mechanisms: agonist treatment enhances receptor/G-protein transduction rather than eliciting uncoupling. J Mol Cell Cardiol 31:413–423
Murad N, Tucci PJF (2000) Isoproterenol-induced hypertrophy may result in distinct left ventricular changes. Clin Exp Pharmacol Physiol 27:352–357
Pick R, Jalil JE, Janicki J et al (1989) The fibrillar nature and structure of isoproterenol-induced myocardial fibrosis in the rat. Am J Pathol 134:365–371
Tang Q, Taylor PB (1984) Regression of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol 62:1141–1146
Deshaies Y, Willemot J, Leblanc J (1981) Protein synthesis, amino acid uptake, and pools during isoproterenol-induced hypertrophy of the rat heart and tibialis muscle. Can J Physiol Pharmacol 59:113–121
Dubus I, Samuel JL, Marotte F et al (1990) β-adrenergic agonists stimulate the synthesis of noncontractile but not contractile proteins in cultured myocytes isolated from adult rat heart. Circ Res 66:867–874
Schluter KD, Frischkopf K, Flesch M et al (2000) Central role for ornithine decarboxylase in β-adrenoceptor-mediated hypertrophy. Cardiovasc Res 45:410–417
Mallov S (1973) Effect of sympathomimetic drugs on protein synthesis in rat heart. J Pharmacol Exp Ther 187:482–494
Wood WG, Lindenmayer GE, Schwartz A (1971) Myocardial synthesis of ribonucleic acid. I. Stimulation by isoproterenol. J Mol Cell Cardiol 3:127–138
Tang Q, Taylor PB, Helbing RK (1987) Catecholamine-induced cardiac hypertrophy. Can J Cardiol 3:311–316
Bartolome J, Huguenard J, Slotkin TA (1980) Role of ornithine decarboxylase in cardiac growth and hypertrophy. Science 210:793–794
Larson DF, Copeland JG, Russell DH (1985) Catecholamine-induced cardiac hypertrophy in a denervated, hemodynamically non-stressed heart transplant. Life Sci 36:2477–2489
Mallov S (1975) Effect of sympathomimetic amines and monoamine oxidase inhibitors on protein synthesis in rat heart. Biochem Pharmacol 25:1645–1651
Clark WA, Rudnick SJ, LaPres JJ et al (1991) Hypertrophy of isolated adult feline heart cells following β-adrenergic-induced beating. Am J Physiol 261:C530–542
Irlbeck M, Muhling O, Iwai T et al (1996) Different response of the rat left and right heart to norepinephrine. Cardiovasc Res 31:157–162
Kizaki K, Momozaki M, Akatsuka K et al (2004) Impaired gene expression of β1-adrenergic receptor, but not stimulatory G-protein Gsα, in rat ventricular myocardium treated with isoproterenol. Biol Pharm Bull 27:1130–1132
Osadchii O, Woodiwiss A, Alves N et al (2005) Mechanisms of preserved baseline cardiac systolic function in rats with adrenergic inotropic downregulation. Life Sci 78:366–375
Osadchii O, Woodiwiss A, Norton G (2006) Contractile responses to selective phosphodiesterase inhibitors following chronic β-adrenoreceptor activation. Pflugers Arch 452:155–163
Tang L, Gao W, Taylor PB (1996) Force-frequency response in isoproterenol-induced hypertrophied rat heart. Eur J Pharmacol 318:349–356
Tang L, Taylor PB (1996) Altered contractile function in isoproterenol-induced hypertrophied rat heart. J Hypertens 14:751–757
Lin YC (1973) Hemodynamics in the rat with isoproterenol-induced cardiac hypertrophy. Res Commun Chem Pathol Pharmacol 6:213–220
Ishizawa M, Mizushige K, Noma T et al (2006) An antioxidant treatment potentially protects myocardial energy metabolism by regulating uncoupling protein 2 expression in a chronic β-adrenergic stimulation rat model. Life Sci 78:2974–2982
Lahlou S, Lima GC, Leao-Filho CSC et al (2000) Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats. Can J Physiol Pharmacol 78:260–265
McQueen AP, Zhang D, Hu P et al (2005) Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol 39:882–892
Meszaros J (1992) Sodium-pump injury and arrhythmogenic transient depolarizations in catecholamine-induced cardiac hypertrophy. Eur J Pharmacol 210:325–331
Meszaros J, Khananshvili D, Hart G (2001) Mechanisms underlying delayed afterdepolarizations in hypertrophied left ventricular myocytes of rats. Am J Physiol 281:H903–914
Chorvatova A, Hart G, Hussain M (2004) Na+/Ca2+ exchange current (I Na/Ca) and sarcoplasmic reticulum Ca2+ release in catecholamine-induced cardiac hypertrophy. Cardiovasc Res 61:278–287
Hayes JS, Pollock GD, Fuller RW (1984) In vivo cardiovascular responses to isoproterenol, dopamine and tyramine after prolonged infusion of isoproterenol. J Pharmacol Exp Ther 231:633–639
Vleeming W, van Rooij HH, Wemer J et al (1990) Modulation of adrenoceptor-mediated cardiovascular effects by short-term in vivo infusion of isoproterenol in rats. J Cardiovasc Pharmacol 16:584–593
Butterfield MC, Chess-Williams R (1993) Potentiation of α-adrenoceptor-mediated responses following chronic β-adrenoceptor stimulation in the rat heart. Br J Pharmacol 108:658–662
Stein B, Bartel S, Kirchhefer U et al (1996) Relation between contractile function and regulatory cardiac proteins in hypertrophied hearts. Am J Physiol 270:H2021–2028
Linck B, Boknik P, Baba HA et al (1998) Long-term beta-adrenoceptor-mediated alteration in contractility and expression of phospholamban and sarcoplasmic reticulum Ca++-ATPase in mammalian ventricle. J Pharmacol Exp Ther 286:531–538
Woodiwiss AJ, Tsotetsi OJ, Sprott S et al (2001) Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 103:155–160
Kitagawa Y, Yamashita D, Ito H et al (2004) Reversible effects of isoproterenol-induced hypertrophy on in situ left ventricular function in rat hearts. Am J Physiol 287:H277–285
Veliotes DG, Woodiwiss AJ, Deftereos DA et al (2005) Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by β-adrenoreceptor activation. Hypertension 45:914–920
Osadchii OE, Norton GR, McKechnie R et al (2007) Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic β-adrenoreceptor activation. Am J Physiol (in press). doi:10.1152/ajpheart.00740.2006
Boknik P, Fockenbrock M, Herzig S et al (2000) Protein phosphatase activity is increased in a rat model of long-term β-adrenergic stimulation. Naunyn-Schmiedeberg’s Arch Pharmacol 362:222–231
Tappia PS, Hata T, Hozaima L et al (2001) Role of oxidative stress in catecholamine-induced changes in cardiac sarcolemmal Ca2+ transport. Arch Biochem Biophys 387:85–92
Meyrelles SS, Mauad H, Mathias SC et al (1998) Effects of myocardial hypertrophy on neural reflexes controlling cardiovascular function. J Auton Nerv Syst 73:135–142
Matthews JM, Falckh PHJ, Molenaar P et al (1996) Chronic (-)-isoprenaline infusion down-regulates β1- and β2-adrenoreceptors but does not transregulate muscarinic cholinoceptors in rat heart. Naunyn-Schmiedeberg’s Arch Pharmacol 353:213–225
Mueller RA, Axelrod J (1968) Abnormal cardiac norepinephrine storage in isoproterenol-treated rats. Circ Res 23:771–778
Mueller RA, Thoenen H (1971) Cardiac catecholamine synthesis, turnover and metabolism with isoproterenol-induced myocytolisis. Cardiovasc Res 5:364–370
Dhalla NS, Balasubramanian V, Goldman J (1971) Biochemical basis of heart function, III. Influence of isoproterenol on the norepinephrine stores in the rat heart. Can J Physiol Pharmacol 49:302–311
Raum WJ, Laks MM, Garner D et al (1984) Norepinephrine increases β-receptors and adenylate cyclase in canine myocardium. Am J Physiol 246:H31–36
Himura Y, Felten SY, Kashiki M et al (1993) Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 88:1299–1309
Dong DE, Yatani A, Mohan A et al (1999) Myocardial β-adrenoceptor down-regulation by norepinephrine is linked to reduced norepinephrine uptake activity. Eur J Pharmacol 384:17–24
Lai LP, Fan THM, Delehanty JM et al (1996) Elevated myocardial interstitial norepinephrine concentration contributes to the regulation of Na+, K+-ATPase in heart failure. Eur J Pharmacol 309:235–241
Meszaros J, Levai G (1992) Catecholamine-induced cardiac hypertrophy uncouples β-adrenoceptors from slow calcium channels. Eur J Pharmacol 210:333–338
Meszaros J, Coutihno JJ, Bryant SM et al (1997) L-type calcium current in catecholamine-induced cardiac hypertrophy in the rat. Exp Physiol 82:71–83
Bryant SM, Shipsey SJ, Hart G (1999) Normal regional distribution of membrane current density in rat left ventricle is altered in catecholamine-induced hypertrophy. Cardiovasc Res 42:391–401
Meszaros J, Ryder K, Hart G (1996) Transient outward current in catecholamine-induced cardiac hypertrophy in the rat. Am J Physiol 271:H2360–2367
Kim CH, Fan THM, Kelly PF et al (1994) Isoform-specific regulation of myocardial Na,K-ATPase α-subunit in congestive heart failure. Circulation 89:313–320
Baek M, Weiss M (2005) Down-regulation of Na+ pump α2 isoform in isoprenaline-induced cardiac hypertrophy in rat: evidence for increased receptor binding affinity but reduced inotropic potency of digoxin. J Pharmacol Exp Ther 313:731–739
Vatner DE, Vatner SF, Nejima J et al (1989) Chronic norepinephrine elicits desensitization by uncoupling the β-receptor. J Clin Invest 84:1741–1748
Chang DHT, Einstein R (1996) Changes in cardiovascular responsiveness to dopexamine and β1- and β2-adrenoceptor function after the chronic treatment of β-adrenoceptor antagonists and agonists in anaesthetized dogs. J Auton Pharmacol 16:269–279
Hayes JS, Wyss VL, Schenck KS et al (1986) Effects of prolonged isoproterenol infusion on cardiac and vascular responses to adrenoceptor agonists. J Pharmacol Exp Ther 237:757–763
Martin SW, Broadley KJ (1994) Effects of chronic intravenous infusions of dopexamine and isoprenaline to rats on D1-, β1-and β2-receptor-mediated responses. Br J Pharmacol 112:595–603
Russell FD, Kompa AR, Molenaar P et al (1994) Regulation of β-adrenoceptors in the guinea-pig sinoatrial node. Naunyn-Schmiedeberg’s Arch Pharmacol 349:463–472
Kaumann AJ, Birnbaumer L (1976) Desensitization of kitten atria to chronotropic, inotropic and adenylyl cyclase stimulating effects of (-) isoprenaline. Naunyn-Schmiedeberg’s Arch Pharmacol 293:199–202
Hedberg A, Mattsson H, Nerme V et al (1984) Effects of in vivo treatment with isoprenaline or prenalterol on beta-adrenoceptor mechanisms in the heart and soleus muscle of the cat. Naunyn-Schmiedeberg’s Arch Pharmacol 325:251–258
Brown L, Sernia C, Newling R et al (1992) Cardiac responses after norepinephrine-induced ventricular hypertrophy in rats. J Cardiovasc Pharmacol 20:316–323
Laycock SK, McMurray J, Kane KA et al (1995) Effects of chronic norepinephrine administration on cardiac function in rats. J Cardiovasc Pharmacol 26:584–589
Marsh JD, Barry WH, Neer EJ et al (1980) Evidence for uncoupling of the beta receptor-adenylate cyclase complex. Circ Res 47:493–501
Marsh JD, Barry WH, Smith TW (1982) Desensitization to the inotropic effect of isoproterenol in cultured ventricular cells. J Pharmacol Exp Ther 223:60–67
Wynne DG, Poole-Wilson PA, Harding SE (1993) Incomplete reversal of β-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 109:1071–1078
Vescovo G, Jones SM, Harding SE et al (1989) Isoproterenol sensitivity of isolated cardiac myocytes from rats with monocrotaline-induced right-sided hypertrophy and heart failure. J Mol Cell Cardiol 21:1047–1061
Jones SM, Kirby MS, Harding SE et al (1990) Adriamycin cardiomyopathy in the rabbit: alterations in contractile proteins and myocyte function. Cardiovasc Res 24:834–842
Vleeming W, van der Wouw PA, Biesebeek JD et al (1989) Density of β-adrenoceptors in rat heart and lymphocytes 48 hours and 7 days after acute myocardial infarction. Cardiovasc Res 23:859–866
Lu X, Barnett DB (1990) Differential rates of down regulation and recovery of rat myocardial β-adrenoceptor subtypes in vivo. Eur J Pharmacol 182:481–486
Kimura H, Miyamoto A, Ohshika H (1993) Down-regulation of β-adrenoceptors and loss of Gsα subunit levels in ventricular myocardium of rats treated with isoproterenol. Life Sci 53:PL171–176
Limas CJ, Limas C (1984) Rapid recovery of cardiac β-adrenergic receptors after isoproterenol-induced “down”-regulation. Circ Res 55:524–531
Bobik A, Campbell JH, Carson V et al (1981) Mechanism of isoprenaline-induced refractoriness of the β-adrenoceptor-adenylate cyclase system in chick embryo cardiac cells. J Cardiovasc Pharmacol 3:541–553
Kompa AR, Molenaar P, Summers RJ (1994) Effect of chemical sympathectomy on (-)-isoprenaline-induced changes in cardiac β-adrenoceptor subtypes in the guinea-pig and rat. J Auton Pharmacol 14:411–423
Molenaar P, Smolich JJ, Russell FD et al (1990) Differential regulation of beta-1 and beta-2 adrenoceptors in guinea-pig atrioventricular conducting system after chronic (-)-isoproterenol infusion. J Pharmacol Exp Ther 255:393–400
Zhao M, Hagler HK, Muntz KH (1996) Regulation of α1-, β1-, and β2-adrenergic receptors in rat heart by norepinephrine. Am J Physiol 271:H1762–1768
Elfellah MS, Reid JL (1990) Regulation of β-adrenoceptors in the guinea-pig left ventricle and skeletal muscle following chronic agonist treatment. Eur J Pharmacol 182:387–392
Zhao M, Muntz KH (1993) Differential downregulation of β2-adrenergic receptors in tissue compartments of rat heart is not altered by sympathetic denervation. Circ Res 73:943–951
El-Demerdash E, Awad AS, Taha RM et al (2005) Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. Pharmacol Res 51:311–318
Leineweber K, Brandt K, Wludyka B et al (2002) Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure. Circ Res 91:1056–1062
Schumacher C, Becker H, Conrads R et al (1995) Hypertrophic cardiomyopathy: a desensitized cardiac beta-adrenergic system in the presence of normal plasma catecholamine concentrations. Naunyn-Schmiedeberg’s Arch Pharmacol 351:398–407
Karliner JS, Simpson PC, Honbo N et al (1986) Mechanisms and time course of beta1-adrenoceptor desensitization in mammalian cardiac myocytes. Cardiovasc Res 20:221–228
Lau C, Burke S, Slotkin T (1982) Maturation of sympathetic neurotransmission in the rat heart. IX. Development of transsynaptic regulation of cardiac adrenergic sensitivity. J Pharmacol Exp Ther 223:675–680
Eschenhagen T, Mende U, Nose M et al (1991) Isoprenaline-induced increase in mRNA levels of inhibitory G-protein α-subunits in rat heart. Naunyn-Schmiedeberg’s Arch Pharmacol 343:609–615
Eschenhagen T, Mende U, Diederich M et al (1992) Long term β-adrenoceptor-mediated up-regulation of Giα and G0α mRNA levels and pertussis toxin-sensitive guanine nucleotide-binding proteins in rat heart. Mol Pharmacol 42:773–783
Mende U, Eschenhagen T, Geertz B et al (1992) Isoprenaline-induced increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart. Naunyn-Schmiedeberg’s Arch Pharmacol 345:44–50
Muller FU, Boheler KR, Eschenhagen T et al (1993) Isoprenaline stimulates gene transcription of the inhibitory G-protein α-subunit Giα2 in rat heart. Circ Res 72:696–700
Reithmann C, Gierschik P, Sidiropoulos D et al (1989) Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells: increase in the level of inhibitory G-protein α-subunits. Eur J Pharmacol 172:211–221
Brown A, Harding SE (1992) Effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol 106:115–122
Jones SM, Hunt NA, Del Monte F et al (1990) Contraction of cardiac myocytes from noradrenaline-treated rats in response to isoprenaline, forskolin and dibutyryl cAMP. Eur J Pharmacol 191:129–140
McMartin L, Summers RJ (1999) Functional analysis of desensitization of the beta-adrenoceptor signalling pathway in rat cardiac tissues following chronic isoprenaline infusion. Br J Pharmacol 127:1012–1020
Tse J, Brackett NL, Kuo JF (1978) Alterations in activities of cyclic nucleotide systems and in β-adrenergic receptor-mediated activation of cyclic AMP-dependent protein kinase during progression and regression of isoproterenol-induced cardiac hypertrophy. Biochim Biophys Acta 542:399–411
Harrison SA, Reifsnyder DH, Gallis B et al (1986) Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29:506–514
Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. J Biol Chem 271:16526–16534
Byus CV, Chubb JM, Huxtable RJ et al (1976) Increase in type I adenosine 3’, 5’-monophosphate-dependent protein kinase during isoproterenol-induced cardiac hypertrophy. Biochem Biophys Res Commun 73:694–702
Horwood DM, Singhal RL (1976) Myocardial protein kinases: II. Isoproterenol-induced changes in the activity of soluble and membrane-bound enzymes of rat left ventricle. J Mol Cell Cardiol 8:29–38
Simpson P, McGrath A, Savion S (1982) Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 51:787–801
Bohm M, Deutsch HJ, Hartmann D et al (1997) Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 30:992–996
Metra M, Nodari S, D’Aloia A et al (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. J Am Coll Cardiol 40:1248–1258
Baker KM, Campanile CP, Trachte GJ et al (1984) Identification and characterization of the rabbit angiotensin II myocardial receptor. Circ Res 54:286–293
Katz AM (1990) Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 22:739–747
Lindpaintner K, Ganten D (1991) The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 68:905–921
Schorb W, Booz GW, Dostal DE et al (1993) Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 72:1245–1254
Regitz-Zagrosek V, Friedel N, Heymann A et al (1995) Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 91:1461–1471
Crawford DC, Chobanian AV, Brecher P (1994) Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 74:727–739
Sadoshima J, Izumo S (1993) Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 73:413–423
Dostal DE, Baker KM (1992) Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Am J Hypertens 5:276–280
Nagano M, Higaki J, Nakamura F et al (1992) Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension 19:708–712
Bos R, Mougenot N, Mediani O et al (2004) Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. J Pharmacol Exp Ther 309:1160–1166
Oliveira EM, Krieger JE (2005) Chronic β-adrenoceptor stimulation and cardiac hypertrophy with no induction of circulating renin. Eur J Pharmacol 520:135–141
Galvez AS, Fiedler JL, Ocaranza MP et al (2005) Perindopril regulates β-agonist-induced cardiac apoptosis. J Cardiovasc Pharmacol 46:255–261
Robert V, Silvestre JS, Charlemagne D et al (1995) Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26:971–978
Weinberger MH, Aoi W, Henry DP (1975) Direct effect of beta-adrenergic stimulation on renin release by the rat kidney slice in vitro. Circ Res 37:318–324
Dostal DE, Booz GW, Baker KM (2000) Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and β-adrenergic stimulation. Basic Res Cardiol 95:485–490
Borges JC, Silva JA, Gomes MA et al (2003) Tonin in rat heart with experimental hypertrophy. Am J Physiol 284:H2263–2268
Nakamuru M, Jackson EK, Inagami T (1986) β-adrenoceptor-mediated release of angiotensin II from mesenteric arteries. Am J Physiol 250:H144–148
Barki-Harrington L, Luttrell LM, Rockman HA (2003) Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist. A functional role for receptor-receptor interaction in vivo. Circulation 108:1611–1618
Duerr RL, Huang S, Miraliakbar HR et al (1995) Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 95:619–627
Duerr RL, McKirnan MD, Gim RD et al (1996) Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 93:2188–2196
Ito H, Hiroe M, Hirata Y et al (1993) Insulin-like growth factor-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87:1715–1721
Sun XW, Ng YC (1998) Effects of norepinephrine on expression of IGF-1/IGF-1R and SERCA2 in rat heart. Cardiovasc Res 37:202–209
Fisher SA, Absher M (1995) Norepinephrine and angiotensin II stimulate secretion of TGF-β by neonatal rat cardiac fibroblasts in vitro. Am J Physiol 268:C910–917
Takahashi N, Calderone A, Izzo NJ et al (1994) Hypertrophic stimuli induce transforming growth factor-β1 expression in rat ventricular myocytes. J Clin Invest 94:1470–1476
Briest W, Homagk L, Rabler B et al (2004) Norepinephrine-induced changes in cardiac transforming growth factor-β isoform expression pattern of female and male rats. Hypertension 44:410–418
Zimmer HG (1997) Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression. J Mol Med 75:849–859
Hannan RD, West AK (1991) Adrenergic agents, but not triiodo-L-thyronine induce c-fos and c-myc expression in the rat heart. Basic Res Cardiol 86:154–164
Bishopric NH, Jayasena V, Webster KA (1992) Positive regulation of the skeletal α-actin gene by Fos and Jun in cardiac myocytes. J Biol Chem 267:25535–25540
Iwaki K, Sukhatme V, Shubeita HE et al (1990) α- and β-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. J Biol Chem 265:13809–13817
Zou Y, Komuro I, Yamazaki T et al (1999) Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J Biol Chem 274:9760–9770
Murray DR, Prabhu SD, Chandrasekar B (2000) Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101:2338–2341
Rathore N, John S, Kale M et al (1998) Lipid peroxidation and antioxidant enzymes in isoproterenol-induced oxidative stress in rat tissues. Pharmacol Res 38:297–303
Ondrejickova O, Dzurba A, Sedlak J et al (1991) Processes linked to the formation of reactive oxygen species are not necessarily involved in the development of isoproterenol-induced hypertrophy of the heart. The effect of stobadine. Biomed Biochim Acta 50:1251–1254
Muller FU, Neumann J, Schmitz W (2000) Transcriptional regulation by cAMP in the heart. Mol Cell Biochem 212:11–17
Muller FU, Boknik P, Horst A et al (1995) cAMP response element binding protein is expressed and phosphorylated in the human heart. Circulation 92:2041–2043
Goldspink PH, Russell B (1996) Physiological role of phosphorylation of the cyclic AMP response element binding protein in rat cardiac nuclei. Cell Tissue Res 285:379–385
Goldspink PH, Russel B (1994) The cAMP response element binding protein is expressed and phosphorylated in cardiac myocytes. Circ Res 74:1042–1049
Muller FU, Boknik P, Knapp J et al (2001) Activation and inactivation of cAMP-response element-mediated gene transcription in cardiac myocytes. Cardiovasc Res 52:95–102
Acknowledgments
Editorial comments suggested by Prof. D. Paul Thomas (University of Wyoming, USA) are greatly appreciated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Osadchii, O.E. Cardiac hypertrophy induced by sustained β-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 12, 66–86 (2007). https://doi.org/10.1007/s10741-007-9007-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-007-9007-4